T-cell activity, as measured by the density of CD3+ and CD8+ T-lymphocytes at the margins and center of tumors, acts as a prognostic biomarker for disease-free survival and overall survival (OS) in early-stage CRC patients independently of TNM stage and MSI status [7, 8]. The gene discussed is CD8A; the disease is colorectal carcinoma.